vimarsana.com

Latest Breaking News On - Second hospital of hebei medical university - Page 1 : vimarsana.com

Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML) | Journal of Translational Medicine

The survival rate for patients with relapsed and refractory acute myeloid leukaemia (R/R-AML) remains poor, and treatment is challenging. Chimeric antigen receptor T cells (CAR-T cells) have been widely used for haematologic malignancies. Current CAR-T therapies for acute myeloid leukaemia mostly target myeloid-lineage antigens, such as CD123 and CD33, which may be associated with potential haematopoietic toxicity. As a lineage-specific receptor, CD7 is expressed in acute myeloid leukaemia cells and T cells but is not expressed in myeloid cells. Therefore, the use of CD7 CAR-T cells for R/R-AML needs to be further explored. In this report, immunohistochemistry and flow cytometry were used to analyse CD7 expression in clinical samples from R/R-AML patients and healthy donors (HDs). We designed naturally selected CD7 CAR-T cells to analyse various functions and in vitro antileukaemic efficacy based on flow cytometry, and xenograft models were used to validate in vivo tumour dynamics. We

11 million locked down in China s Hebei province to prevent spread of new coronavirus outbreak

11 million locked down in China s Hebei province to prevent spread of new coronavirus outbreak Dawn Liu and Adela Suliman and Ed Flanagan and Eric Baculinao and Will Xu © Provided by NBC News BEIJING It took just 39 new coronavirus cases for health authorities in China to put almost 11 million people into lockdown in the city of Shijiazhuang. Health officials took no chances on Wednesday, sealing off the capital of the industrial Hebei province and ordering a mass testing drive. Travel restrictions were put in place in the remainder of the region, which encircles China s capital Beijing and is home to some 76 million people.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.